

## Certificate of Analysis

### SGK3, unactive

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-648, 14-648-K, 14-648M

Parent Lot # 31110U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal 6His-tagged, recombinant, human SGK3 unactive, amino acids 119–end. Expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>/NTA agarose. Purity 62.7% by SDS-PAGE and Coomassie blue staining. MW = 46.8kDa.

**Formulation:** 0.49mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.03% Brij-35, 0.1mM EGTA, 270mM sucrose, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol. Frozen solution.

**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Specific Activity (Parent lot# 31110U):** As provided, this lot demonstrated 18% of maximum activity. Activated by phosphorylation with PDK1 (cat# 14-452).

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Activation Assay:** Unactive SGK3 was activated using PDK1 (cat# 14-452). And the increased activity against crosstide determined. The activation and subsequent assay is described on page two. Results of this assay are shown below

**MS Tryptic Fingerprint:** Confirmed identity as SGK3 with the translated native sequence listed on page three.

Active PDK1	Unactive SGK3	Mean cpm	Comments
36ng	None	1773	Background
None	22.8ng	6657	Background
36ng	22.8ng	7256	Kinase activity



## Certificate of Analysis

### Kinase Cascade Assay Protocol

#### Stock Solutions:

1. **10 x SGK3 Activation Buffer:** 500mM Tris/HCl, pH7.5, 1mM EGTA, 1% 2-mercaptoethanol
2. **5 x SGK3 Assay Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
3. **Enzyme Dilution Buffer:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 5% glycerol, 0.01% Brij-35, 0.1% 2-mercaptoethanol, 1mg/ml BSA.
4. **Magnesium/ATP Cocktail (5 x stock):** 500 $\mu$ M cold ATP and 50mM magnesium acetate.
5.  **$[\gamma\text{-}^{33}\text{P}]\text{ATP}$ :** 2.5 x magnesium acetate/ $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  cocktail: 25mM MgAc and 0.25mM ATP to which is added  $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  (specific activity approximately 500 - 800cpm/pmol as required.)
6. **PDK1, active (Catalogue# 14-452):** Use at a final assay concentration of 0.025 $\mu$ M). Prepare a 0.0147mg/ml stock and add 5 $\mu$ l of stock per assay point.
7. **SGK3, unactive:** Use at a final concentration of 2 $\mu$ M (0.0936mg/ml). Prepare a 0.468mg/ml stock and add 5 $\mu$ l of stock per assay point.
8. **Modified Crosstide(GRPRTSSFAEGKK):** Use a final assay concentration of 250 $\mu$ M. Make a 2.5mM stock. Add 2.5 $\mu$ l of stock per assay point.

#### Assay Procedure:

##### **Stage One:** *Activation of SGK3 by PDK1*

1. Add 5 $\mu$ l of 10 x SGK3 activation buffer to a microcentrifuge tube.
2. Add **5 $\mu$ l of SGK3, unactive.**
3. Add 5 $\mu$ l of PDK1, active.
4. Add 30 $\mu$ l of dH<sub>2</sub>O.
5. Add 5 $\mu$ l of Magnesium/ATP cocktail.
6. Incubate for 30 minutes at 30°C.
7. Stop reaction by diluting 10–50 fold and placing on ice.

##### **Stage Two:** *Phosphorylation of modified Crosstide by SGK3 (96 well plate format):*

1. Add 5 $\mu$ l of 5 x reaction buffer per assay to wells.
2. Add 2.5 $\mu$ l of **modified Crosstide (GRPRTSSFAEGKK).**
3. Add **2.5 $\mu$ l (1–9ng) SGK3,active.**
4. Add 5 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of diluted  $[\gamma\text{-}^{33}\text{P}]\text{ATP}$  mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
8. Transfer a 15 $\mu$ l aliquot onto the appropriate area of a **P30 Filtermat.**
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

## Certificate of Analysis

### SGK3 Sequence Information

<b><u>Protein</u></b>	Human SGK3
<b><u>Tags</u></b>	N-Terminal 6His
<b><u>Native sequence</u></b>	M31 of the recombinant protein is equivalent to M119 of human SGK3
<b><u>Accession number</u></b>	GenBank NM_013257

#### ***Recombinant SGK3 amino acid sequence:***

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MDSPKHQSDP SEEDERSSQ K LHSTSQNIN
61 LGPSGNPHAK PTDFDFLKVI GKGSFGKVLL AKRKLDGKFY AVKVLQKKIV LNRKEQKHIM
121 AERNVLLKNV KHPFLVGLHY SFQTTEKLYF VLDFVNGGEL FFHLQRERSF PEHRARFYAA
181 EIASALGYLH SIKIVYRDLK PENILLDSVG HVVLTDFGLC KEGIAISDTT TTF CGTPEYL
241 APEVIRKQPY DNTVDWVCLG AVLYEMLYGL PPFYCRDVAE MYDNILHKPL SLRPGVSLTA
301 WSILEELLEK DRQNRGAKE DFLEIQNHPF FESLSWADLV QKKIPPPFNP NVAGPDDIRN
361 FDTAFTEETV PYSVCVSSDY SIVNASVLEA DDAFVGFSSYA PPS EDLFL

```

#### ***Recombinant SGK3 nucleotide sequence:***

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac c gaaaacctg
61 tattttcagg gcgccatgga tccggaattc atggacagtc caaaacacca gtcagatcca
121 tctgaagatg aggatgaaag aagttctcag aagctacact ctacctcaca gaacatcaac
181 ctgggaccgt ctggaatcc tcatgcaaaa ccaactgact ttgatttctt aaaagttatt
241 ggaaaaggca gctttggcaa ggttcttctt gcaaaacgga aactggatgg aaaattttat
301 gctgtcaaag tgttacagaa aaaaatagtt ctcaacagaa aagagcaaaa acatattatg
361 gctgaacgta atgtgctctt gaaaaatgtg aaacatccgt ttttggttgg attgcattat
421 tccttccaaa caactgaaaa gctttatctt gttctggatt ttgttaatgg aggggagctt
481 tttttccact tacaagaga acggtccttt cctgagcaca gagctagggt ttacgctgct
541 gaaattgcta gtgcattggg ttacttacat tccatcaaaa tagtatacag agacttgaaa
601 ccagaaaata ttcttttggg ttcagtagga catgttgctt taacagattt tgggctttgt
661 aaagaaggaa ttgctatttc tgacaccact accacatctt gtgggacacc agagtatctt
721 gcacctgaag taattagaaa acagccctat gacaatactg tagattgggt gtgccttggg
781 gctgttctgt atgaaatgct gtatggattg cctccttttt attgccgaga tgttgctgaa
841 atgtatgaca atatccttca caaaccccta agtttgaggc caggagttag tcttacagcc
901 tgggccattc tggagaact cctagaaaaa gacaggcaaa atcgacttgg tgccaaggaa
961 gactttcttg aaattcagaa tcatcctttt tttgaatcac tcagctgggc tgaccttgta
1021 caaaagaaga ttccaccacc atttaatcct aatgtggctg gaccagatga tatcagaaac
1081 tttgacacag catttacaga agaaacagtt ccatattctg tgtgtgtatc ttctgactat
1141 tctatagtga atgccagtgt attggaggca gatgatgcat tcgttggttt ctcttatgca
1201 cctccttcag aagacttatt tttgtga

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services